Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies

Andrew S. Kennedy, Riad Salem

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

Radioembolization using radioactive yttrium-90-labeled microspheres is gaining a stronger foothold in the management of primary and metastatic hepatic cancers. The expanding literature reveals good and encouraging results in both retrospective and prospective reports as demonstrated by low acute or late toxicity and high response rates. This treatment modality, which is most beneficial in patients with good liver reserve and low Eastern Cooperative Oncology Group performance status, has led to improved time to liver progression and extended overall patient survival. Although the phase III trials of radioembolization are ongoing as a first-line treatment of patients with metastatic colorectal cancer, there are sufficient phase II and retrospective clinical data supporting its use in salvage therapy for most patients. Patients with hepatocellular cancer, neuroendocrine tumors, and other primary sites, including breast and lung, have also shown promising response and survival increases in multi-institutional experiences.

Original languageEnglish (US)
Pages (from-to)163-175
Number of pages13
JournalCancer Journal
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Yttrium
Microspheres
Liver
Neoplasms
Liver Neoplasms
Salvage Therapy
Survival
Neuroendocrine Tumors
Colorectal Neoplasms
Breast
Lung
Therapeutics

Keywords

  • Brachytherapy
  • Breast
  • Colorectal
  • Hepatocellular
  • Liver
  • Neuroendocrine
  • SIRT
  • Yttrium-90

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{866d8dba83e441348e014de2d84f8d51,
title = "Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies",
abstract = "Radioembolization using radioactive yttrium-90-labeled microspheres is gaining a stronger foothold in the management of primary and metastatic hepatic cancers. The expanding literature reveals good and encouraging results in both retrospective and prospective reports as demonstrated by low acute or late toxicity and high response rates. This treatment modality, which is most beneficial in patients with good liver reserve and low Eastern Cooperative Oncology Group performance status, has led to improved time to liver progression and extended overall patient survival. Although the phase III trials of radioembolization are ongoing as a first-line treatment of patients with metastatic colorectal cancer, there are sufficient phase II and retrospective clinical data supporting its use in salvage therapy for most patients. Patients with hepatocellular cancer, neuroendocrine tumors, and other primary sites, including breast and lung, have also shown promising response and survival increases in multi-institutional experiences.",
keywords = "Brachytherapy, Breast, Colorectal, Hepatocellular, Liver, Neuroendocrine, SIRT, Yttrium-90",
author = "Kennedy, {Andrew S.} and Riad Salem",
year = "2010",
month = "3",
day = "1",
doi = "10.1097/PPO.0b013e3181d7e8cf",
language = "English (US)",
volume = "16",
pages = "163--175",
journal = "Cancer Journal",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. / Kennedy, Andrew S.; Salem, Riad.

In: Cancer Journal, Vol. 16, No. 2, 01.03.2010, p. 163-175.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies

AU - Kennedy, Andrew S.

AU - Salem, Riad

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Radioembolization using radioactive yttrium-90-labeled microspheres is gaining a stronger foothold in the management of primary and metastatic hepatic cancers. The expanding literature reveals good and encouraging results in both retrospective and prospective reports as demonstrated by low acute or late toxicity and high response rates. This treatment modality, which is most beneficial in patients with good liver reserve and low Eastern Cooperative Oncology Group performance status, has led to improved time to liver progression and extended overall patient survival. Although the phase III trials of radioembolization are ongoing as a first-line treatment of patients with metastatic colorectal cancer, there are sufficient phase II and retrospective clinical data supporting its use in salvage therapy for most patients. Patients with hepatocellular cancer, neuroendocrine tumors, and other primary sites, including breast and lung, have also shown promising response and survival increases in multi-institutional experiences.

AB - Radioembolization using radioactive yttrium-90-labeled microspheres is gaining a stronger foothold in the management of primary and metastatic hepatic cancers. The expanding literature reveals good and encouraging results in both retrospective and prospective reports as demonstrated by low acute or late toxicity and high response rates. This treatment modality, which is most beneficial in patients with good liver reserve and low Eastern Cooperative Oncology Group performance status, has led to improved time to liver progression and extended overall patient survival. Although the phase III trials of radioembolization are ongoing as a first-line treatment of patients with metastatic colorectal cancer, there are sufficient phase II and retrospective clinical data supporting its use in salvage therapy for most patients. Patients with hepatocellular cancer, neuroendocrine tumors, and other primary sites, including breast and lung, have also shown promising response and survival increases in multi-institutional experiences.

KW - Brachytherapy

KW - Breast

KW - Colorectal

KW - Hepatocellular

KW - Liver

KW - Neuroendocrine

KW - SIRT

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=77951478799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951478799&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181d7e8cf

DO - 10.1097/PPO.0b013e3181d7e8cf

M3 - Review article

VL - 16

SP - 163

EP - 175

JO - Cancer Journal

JF - Cancer Journal

SN - 0765-7846

IS - 2

ER -